Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study

Multiple Sclerosis Journal

Volumn 20, Issue 4, 2014, Pages 464-470

  Havrdova, Eva ^a   Giovannoni, Gavin ^b   Stefoski, Dusan ^c   Forster, Samantha ^d   Umans, Kimberly ^e   Mehta, Lahar ^e   Greenberg, Steven ^f   Elkins, Jacob ^e  

^a CHARLES UNIVERSITY   (Czech Republic)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d Excel Scientific Solutions ^*  (United Kingdom)

^e BIOGEN   (United States)

^f ABBVIE INC   (United States)

Author keywords

clinical endpoints; induction of remission; magnetic resonance imaging; radiological endpoints; Relapsing remitting multiple sclerosis

Indexed keywords

DACLIZUMAB; GADOLINIUM; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DISABILITY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT; DOSE RESPONSE; DRUG DOSE COMPARISON; NEUROIMAGING; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; TREATMENT DURATION;

CLINICAL ENDPOINTS; INDUCTION OF REMISSION; MAGNETIC RESONANCE IMAGING; RADIOLOGICAL ENDPOINTS; RELAPSING-REMITTING MULTIPLE SCLEROSIS;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896139362     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513502113     Document Type: Article

References (24)

1. World Health Organization and The Multiple Sclerosis International Federation. Atlas multiple sclerosis resources in the world. http://www.who.int/mental-health/neurology/Atlas-MS-WEB.pdf (2008, accessed 10 July 2012).
2. Dutta R, Trapp BD. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol. 2011 ; 93: 1-12
3. Trapp BD, Nave KA. Multiple sclerosis: An immune or neurodegenerative disorder?. Annu Rev Neurosci. 2008 ; 31: 247-269
4. Loma I, Heyman R. Multiple sclerosis: Pathogenesis and treatment. Curr Neuropharmacol. 2011 ; 9: 409-416
5. Havrdova E, Galetta S, Stefoski D, et al. Freedom from disease activity in multiple sclerosis. Neurology. 2010 ; 74: S3 - S7
6. Fox EJ, Rhoades RW. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis. Curr Opin Neurol. 2012 ; 25: S11 - S19
7. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: Post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 2011 ; 10: 338-348
8. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: A retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009 ; 8: 254-260
9. Martin R. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clin Immunol. 2012 ; 142: 9-14
10. Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): A phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010 ; 9: 381-390
11. Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): A randomised, double-blind, placebo-controlled trial. Lancet. 2013 ; 381: 2167-2175
12. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005 ; 58: 840-846
13. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983 ; 33: 1444-1452
14. Freedman M, O'Connor P, Wolinsky J, et al. Teriflunomide increases the proportion of patients free from disease activity in the TEMSO phase III study. Neurology. 2012 ; 78:
15. Giovannoni G, Cook S, Rammohan K, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: A post-hoc and subgroup analysis. Lancet Neurol. 2011 ; 10: 329-337
16. Giovannoni G, Gold R, Kappos L, et al. Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with BG-12: Findings from the DEFINE study. J Neurol. 2012 ; 259: S106
17. Chehata JC, Hassell AB, Clarke SA, et al. Mortality in rheumatoid arthritis: Relationship to single and composite measures of disease activity. Rheumatology (Oxford). 2001 ; 40: 447-452
18. Emery P, Gabay C, Kraan M, et al. Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int. 2007 ; 27: 793-806
19. Neogi T, Felson DT. Composite versus individual measures of disease activity in rheumatoid arthritis. J Rheumatol. 2008 ; 35: 185-187
20. Kappos L, Arnason BGW, Comi G, et al. High proportion of patients free from disease activity in all 3 arms of the high-dose Betaferon (R) trial. J Neurol. 2008 ; 255: 36
21. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010 ; 362: 416-426
22. Giovannoni G, Gold R, Kappos L, et al. Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with BG-12: Findings from the DEFINE study. J Neurol. 2012 ; 259: S106
23. Cohen JA, Reingold SC, Polman CH, et al. Disability outcome measures in multiple sclerosis clinical trials: Current status and future prospects. Lancet Neurol. 2012 ; 11: 467-476
24. Rudick RA, Lee JC, Simon J, et al. Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study. Ann Neurol. 2006 ; 60: 236-242